We are all different. It’s what makes us unique. Companies are all too aware of this, with experiences and products evolving to cater to personal needs and preferences. From mixing custom skin care formulations to Spotify music recommendations, personalised experiences are more memorable and valuable to the customer. The same goes for medicine. Personalisation means
Read More
Breakthrough clinical trials into new treatments for bone marrow and liver cancer will soon commence after experienced institutional biotech investors with positive track records in companies such as Viralytics, Ophthea and Avita committed $7.2 million towards funding the trials for Pharmaxis (ASX: PXS) and their hero drug PXS-5505. Unlike other cancer treatment drugs on the
Read More
“Published” is an accolade that many scientists strive for. Showcasing your work and communicating your results to peers feels good, regardless of age. The setting of scientific show and tell is within scientific journals, offering an enduring record of a scientist’s findings and impact on the world (vastly less obtrusive than being sat down and
Read More
Necessity is the mother of all invention, and seeing an opportunity, Avecho Biotechnology (ASX: AVE) has set about innovating a new livestock feed additive. The development of a new feed additive for animal use comes in anticipation of the European Union’s impending ban on livestock feeds with zinc oxide levels above a certain level. Zinc
Read More
One of the world’s most respected surgeons in the field of burns and trauma recovery will lead world-first clinical trials aiming to stop scars forming, particularly after burn injuries, utilising the latest discovery by biopharmaceuticals company Pharmaxis (ASX: PXS). The discovery, known as PXS-6302 has shown promising pre‐clinical results in inhibiting the enzymes that play
Read More